<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02975219</url>
  </required_header>
  <id_info>
    <org_study_id>2016/304</org_study_id>
    <nct_id>NCT02975219</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Using Molecular Fluorescence Guided Surgery in Endometriosis</brief_title>
  <acronym>Endo-light</acronym>
  <official_title>Determine the Feasibility of Detecting Endometriosis During Surgery Using a Molecular Targeted Fluorescent Imaging Tracer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Incomplete resection of endometriosis lesions often results in recurrence of symptoms and the
      need for repeated surgery, with considerable associated morbidity. The aim of this pilot
      project is to determine the feasibility of fluorescence imaging to improve the treatment of
      endometriosis in the future.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tracer accumulation of bevacizumab-800cw in endometriosis lesions assessed by ex vivo measurement of the mean fluorescent intensity correlated to histopathology</measure>
    <time_frame>within 6 months after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>within two weeks after tracer injection</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4.5mg Bevacizumab-800CW intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab-800CW</intervention_name>
    <description>4.5mg Bevacizumab-800CW will be administered intravenously three days prior to surgery</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>Bevacizumab-IRDye800CW</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females aged â‰¥ 18 years

          2. Scheduled for surgery for the treatment of endometriosis

          3. WHO performance score of 0-2

          4. Written informed consent

             For female subjects who are of childbearing potential, are premenopausal with intact
             reproductive organs or are less than 2 years post-menopausal:

          5. A negative serum pregnancy test prior to receiving the tracer

          6. Willing to ensure that she or her partner uses effective contraception during the
             trial and for 6 months thereafter.

        Exclusion Criteria:

          1. Medical or psychiatric conditions that compromise the patient's ability to give
             informed consent

          2. Pregnancy

          3. History of infusion reactions to Bevacizumab or other monoclonal antibody therapies

          4. Significant renal, cardiac, or pulmonary disease (ASA III-IV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gooitzen van Dam, prof dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gooitzen van Dam, prof dr</last_name>
    <phone>0503610183</phone>
    <email>g.m.van.dam@umcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Go M. van Dam, MD, PhD</last_name>
      <phone>+31 50 361 0183</phone>
      <email>g.m.van.dam@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Go M. van Dam, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>G.M. van Dam</investigator_full_name>
    <investigator_title>prof. dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

